Table 1.
Study group characteristics for ADAMTS-4 and BMP-1 immunohistochemistry analysis of kidney biopsy tissue samples.
| CTRL N = 8 |
NKB N = 19 |
TXCI N = 34 |
TXCI-TX0 PAIRS N = 15 | ||
|---|---|---|---|---|---|
| TXCI (N = 15) | TX0 (N = 15) | ||||
| AGE (YEARS) | 53 ± 13 | 43 ± 17 | 50 ± 16 | 51 ± 44 | 51 ± 7 |
| SEX (% MALE) | 2 (25%) | 7 (37%) | 28 (82%) | 14 (93%) | 6 (40%) |
| BMI | 24.3 ± 4.6 | 26.1 ± 5.7 | 27.1 ± 5.4 | 27.9 ± 18.5 | 25.6 ± 2.2 |
| EGFR (ML/MIN) | 108 ± 28 | 56 ± 36 | 37 ± 16 | 38 ± 64 | 91 ± 22 |
| 24-PROT G/L | - | 3.27 ± 2.74 | 1.53 ± 1.50 | 1.22 ± 5.46 | - |
| CKD | N (%) | N (%) | N (%) | N (%) | N (%) |
| NO CKD | 8 (100) | 0 | 0 | 0 | 14 (93) |
| CKD-1 | 5 (26.3) | 0 | 0 | 1 (6.7) | |
| CKD-2 | 4 (21.1) | 3 (8.8) | 1 (6.7) | 0 | |
| CKD-3 | 2 (10.5) | 20 (58.8) | 9 (60) | 0 | |
| CKD-4 | 6 (31.6) | 10 (29.4) | 5 (33.3) | 0 | |
| CKD-5 | 2 (10.5) | 1 (2.9) | 0 | 0 | |
| COMORBIDITIES | N (%) | N (%) | N (%) | N (%) | N (%) |
| AH | 4 (50) | 12 (63.2) | 31 (91.2) | 13 (86.6) | 6 (40) |
| DM | 0 | 0 | 9 (26.5) | 5 (33.3) | 0 |
| SMOK | 0 | 6 (31.6) | 5 (14.7) | 1 (6.7) | 1 (6.7) |
| HLP | 0 | 9 (47.4) | 13 (38.2) | 5 (33.3) | 0 |
| CAD | 0 | 0 | 4 (11.8) | 1 (6.7) | 0 |
| ATH | 0 | 2 (10.5) | 4 (11.8) | 13 (86.6) | 0 |
| KIDNEY DISEASE | N (%) | N (%) | N (%) | N (%) | N (%) |
| NB | 8 (100) | 0 | 2 (5.8) | 2 (13.3) | 13 (86.6) |
| GN | - | 17 (89.5) | 4 (11.7) | 1 (6.6) | - |
| HTN | - | 1 (5.3) | - | - | - |
| ANCA VS | - | 1 (5.3) | - | - | - |
| TCR | - | - | 2 (5.8) | 1 (6.6) | - |
| ABMR | - | - | 5 (14.7) | 1 (6.6) | - |
| TCR + ABMR | - | - | 4 (11.7) | 1 (6.6) | - |
| BKVAN | - | - | 3 (8.8) | 3 (20) | - |
| NC | - | 0 | 14 (41.1) | 6 (40) | 2 (13.3) |
| ATI | 6 (75) | 5 (26.3) | 8 (23.5) | 3 (20) | 8 (53.3) |
CKD, chronic kidney disease (defined by KDIGO guidelines (Rf); CTRL, control group samples from kidney donor nephrectomies without any evidence of CKD; eGFR > 90 mL/min, absence of proteinuria or structural abnormalities; NKB, native kidney biopsy group; TXCI, clinically indicated transplant biopsy group; TX0, zero time kidney transplant biopsyfor zero-time biopsies and for CTRL clinical data from kidney donors were used; N, number of subjects; BMI, body mass index; eGFR, estimated glomerular filtration (CKD-EPI formula used); 24-h PROT, 24-h proteinuria in g/24 h urine collection (data for donors not available—NA; all donors negative were negative for protein in urine by dipstick protein trace); CKD stage, chronic kidney disease stage: 0—no CKD (eGFR ≥ 90 mL/min, without kidney damage), 1 (eGFR ≥ 90 + presence of kidney damage); 2 (eGFR 60–90 + presence of kidney damage); 3 (eGFR 30–59); 4 (eGFR 15–29); 5 (eGFR ≤ 15); AH, arterial hypertension; DM, diabetes mellitus; SMOK, smoking; HLP, hyperlipoproteinemia; CAD, coronary artery disease; ATH, any atherosclerotic event (cardiovascular or cerebrovascular or peripheral artery disease); KIDNEY DISEASE, underlying histopathologic diagnosis of kidney disease; NB, normal biopsy; GN, primary glomerular disease; HTN, hypertensive kidney disease; ANCAVS, ANCA vasculitis; TCR, T-cell-mediated rejection; ABMR, antibody mediated rejection; TCR + ABMR, combined rejection; BKVAN, BK virus-associated nephropathy; NC, nonspecific chronic changes without criteria for specific diagnosis; ATI, acute tubular injury.